Key Points Multicancer screening technologies are advancing rapidly. Grail is one of the leaders in the cancer screening space. 10 stocks we like better than Grail › Despite decades of progress in fighting it, cancer remains deadly. It is the second-leading cause of death in the United States, behind only heart disease. Early detection and screening are two of the most powerful tools against the disease -- they lead to higher survival rates, less invasive treatments, fewer side effects, and a high ...

GRAIL (NasdaqGS:GRAL) FY Conference September 24, 2025 08:00 AM ET Company ParticipantsJoshua Ofman - PresidentConference Call ParticipantsEve Burstein - US Life Science Tools & Diagnostics AnalystEve BursteinIt's a hardy group that's here at 8:01 A.M. I think there'll be a bigger group at about 8:05 A.M., but we'll go ahead and get started because I have a lot to ask. Excited to be here. Thank you guys all for being here. For anyone that doesn't know me, my name is Eve Bernstein. I cover U.S. life science ...

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, Respectively MENLO PARK, Calif. , Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a health ...

GRAIL, Inc. (NASDAQ:GRAL) is one of the 11 Best Performing IPOs in the Last 2 Years. Major sales by top executives at the company follow a strong positive second quarter. GRAIL Gains Momentum Post-IPO Amid Strong Sales, Partnerships, and Executive Share Activity Photo by National Cancer Institute on Unsplash On August 12, 2025, GRAIL, Inc. (NASDAQ:GRAL) reported revenue of $35.5 million for the second quarter, surpassing the previous by 11%. Strong demand for the company’s products was exemplified by s ...

In this article, we will be looking at the 11 best performing IPOs in the last 2 years.The market environment has been heavily influenced by the changes in monetary policies and global economic uncertainties. Sticky consumer price inflation had to be weighed against the U.S. labor market, which has been going soft recently, while investors are looking forward to a potential first rate cut this week from the Federal Reserve. According to Reuters, futures currently have about 70 basis points of cuts priced ov ...

We came across a bullish thesis on GRAIL, Inc. on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on GRAL. GRAIL, Inc.'s share was trading at $32.42 as of September 3rd. Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion Photo by National Cancer Institute on Unsplash GRAIL (NASDAQ: GRAL) represents a compelling risk-reward opportunity in early cancer detection through its Galleri blood test, the first commercially viable multi-cancer early detection (MCED) ...

Accessibility StatementSkip Navigation MENLO PARK, Calif., Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 2 Annual Healthcare Forum on Wednesday, Sep. 24 at 8:00 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast wil ...

PresentationYuko OkuEquity Analyst Hi, everyone. I'm Yuko Oku, and I'm on the life science tools and diagnostics team at Morgan Stanley. Before we kick it off for important disclosures, please see Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep. With that, it's my pleasure to host GRAIL today. And from the company, we have CEO, Bob Ragusa; and CFO, Aaron Freidin. Thank you. ...

GRAIL (NasdaqGS:GRAL) FY Conference September 09, 2025 01:50 PM ET Company ParticipantsAaron Freidin - CFOYuko Oko - HostBob Ragusa - CEOYuko OkoHi, everyone. I'm Yuko Oko, and I'm on the Life Science Tools and Diagnostics team at Morgan Stanley. Before we kick it off, for important disclosures, please see Morgan Stanley's research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep. With that, it's my pleasure to host ...

公司动态 - 公司管理层将于2025年9月9日东部时间下午1:50在摩根士丹利第23届年度全球医疗健康会议上进行演讲 [1] - 演讲将通过公司官网投资者关系栏目提供实时及回放网络直播 回放内容将在活动结束后保留至少30天 [2] 公司业务与技术 - 公司致力于通过早期癌症检测降低全球癌症负担 核心技术包括下一代测序技术、大规模临床研究及先进机器学习与自动化软件 [3] - 公司采用靶向甲基化检测平台 支持筛查与精准肿瘤学的全流程护理 涵盖多癌种早期检测、风险分层、微小残留病灶监测及生物标志物分型等领域 [3] - 公司总部位于加利福尼亚州门洛帕克 同时在华盛顿特区、北卡罗来纳州和英国设有分支机构 [3]